GLENMARK PHARMACEUTICALS
Back to Income Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Consolidated Net Profit History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Consolidated Net Profit | ₹297 Cr | ₹942 Cr | ₹970 Cr | ₹776 Cr | ₹925 Cr |
What is the latest Consolidated Net Profit of GLENMARK PHARMACEUTICALS ?
Year | Consolidated Net Profit |
---|---|
Mar2024 | ₹297 Cr |
Mar2023 | ₹942 Cr |
Mar2022 | ₹970 Cr |
Mar2021 | ₹776 Cr |
Mar2020 | ₹925 Cr |
How is Consolidated Net Profit of GLENMARK PHARMACEUTICALS Trending?
Years | Consolidated Net Profit | % Change | |
---|---|---|---|
Mar2024 | ₹297 Cr | -68.44 | |
Mar2023 | ₹942 Cr | -2.92 | |
Mar2022 | ₹970 Cr | 25.01 | |
Mar2021 | ₹776 Cr | -16.11 | |
Mar2020 | ₹925 Cr | - |
Compare Consolidated Net Profit of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹62,836.1 Cr | 2.1% | 34.1% | 56.5% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹408,667.0 Cr | 1.8% | 3.4% | 7.3% | Stock Analytics | |
DIVIS LABORATORIES | ₹180,131.0 Cr | -0.7% | 3.8% | 49.3% | Stock Analytics | |
CIPLA | ₹119,745.0 Cr | -0.2% | -1.1% | -2.8% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹118,603.0 Cr | 5.8% | 8.6% | 17.3% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,429.0 Cr | 0.7% | -3.8% | -7.3% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 2.1% |
34.1% |
56.5% |
SENSEX | -1.1% |
0.8% |
2.2% |
You may also like the below Video Courses